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Background: This study aimed to determine the number of people living with HIV receiving antiretroviral therapy
(ART) between 2006 and 2013 in Germany by using the available numbers of antiretroviral drug prescriptions and
treatment data from the ClinSurv HIV cohort (CSH).
Methods: The CSH is a multi-centre, open, long-term observational cohort study with an average number of 10.400
patients in the study period 2006–2013. ART has been documented on average for 86% of those CSH patients and
medication history is well documented in the CSH.
The antiretroviral prescription data (APD) are reported by billing centres for pharmacies covering >99% of
nationwide pharmacy sales of all individuals with statutory health insurance (SHI) in Germany (~85%). Exactly one
thiacytidine-containing medication (TCM) with either emtricitabine or lamivudine is present in all antiretroviral
fixed-dose combinations (FDCs). Thus, each daily dose of TCM documented in the APD is presumed to be
representative of one person per day receiving ART. The proportion of non-TCM regimen days in the CSH was
used to determine the corresponding number of individuals in the APD.
Results: The proportion of CSH patients receiving TCMs increased continuously over time (from 85% to 93%;
2006–2013). In contrast, treatment interruptions declined remarkably (from 11% to 2%; 2006–2013). The total
number of HIV-infected people with ART experience in Germany increased from 31,500 (95% CI 31,000-32,000)
individuals to 54,000 (95% CI 53,000-55,500) over the observation period (including 16.3% without SHI and persons
who had interrupted ART). An average increase of approximately 2,900 persons receiving ART was observed
annually in Germany.
Conclusions: A substantial increase in the number of people receiving ART was observed from 2006 to 2013 in
Germany.
Currently, the majority (93%) of antiretroviral regimens in the CSH included TCMs with ongoing use of FDCs. Based
on these results, the future number of people receiving ART could be estimated by exclusively using TCM
prescriptions, assuming that treatment guidelines will not change with respect to TCM use in ART regimens.
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Combined antiretroviral therapy (ART) as a standard of care
has dramatically reduced mortality and morbidity and has
led to an enormous increase in quality of life among people
infected with HIV [1,2]. In most patients who receive ART,
progression to AIDS or death is increasingly rare [3-5], and
their life expectancies have significantly improved [6-8].
However, ART is a complex and lifelong therapy that must
be well monitored, coordinated and tracked. Although ART
is still not available for a large number of people in need, es-
pecially in developing countries [9], the number of people
living with HIV who are receiving treatment is increasing
worldwide [9]. In industrialised countries, a large number of
people living with HIV are under treatment [10]. As HIV
has become a chronic disease, an increasing number of
people must be treated for decades, making it an important
economic and public health issue to gain information on
this group. Information on the current number of people
living with HIV receiving ART in Germany is scarce owing
to a lack of data, and access to personal-level drug prescrip-
tion data is forbidden because of data protection.
HIV treatment in Germany is characterized by a
decentralised structure. Medical care is mainly provided
by specialized outpatient centres and office-based HIV
specialists, and unlike in many countries people can
consult a doctor of their own choice at any time and
anywhere in the country. Furthermore, health care in
Germany is compulsory for all German citizens and legal
residents and is mostly provided by statutory health in-
surance (SHI) or private health insurance (PHI) [11-13].
SHI occupies a central position in the German health
care system. Approximately 85% of German residents
are covered by SHI, and nearly 60% of the total health
expenditures are borne by SHI [12]. SHI reimburses
pharmacies for the prescriptions of those who are cov-
ered via specialised pharmacy billing centres. Therefore,
the prescription details are electronically recorded. The
recording and use of these data are regulated by the so-
cial security law (§300 SGB V). Data from health services
research such as electronically recorded pharmacy data
are being increasingly used for research in Germany.
Nevertheless, public health studies using data represent-
ing nearly all persons covered by SHI are scarce.
The prescription data include all antiretroviral drugs,
regardless of whether they are for permanent or short-
term therapies, e.g., post-exposure prophylaxis (PEP).
No individual information and, therefore no indications,
are available. In contrast, the prospective multi-centre
observational German ClinSurv HIV cohort (CSH) on-
going since 1999 is the largest available nationwide
source of people infected with HIV and collects detailed
information on the initiation, composition and discon-
tinuation of individuals’ daily ART from their participat-
ing centres [14].Since the approval of the first antiretroviral agent, at
least in the industrialised world, more than 30 antiretro-
viral pharmaceuticals, either single-drug formulations or
fixed-dose combinations, are available for the treatment
of HIV infection [15]. Nucleoside/nucleotide reverse
transcriptase inhibitors (NRTIs) are still the main com-
ponents of antiretroviral drug combinations [16] and are
recommended as an element of any first-line antiretro-
viral regimen by therapy guidelines [17-19]. Currently, a
combination of three antiretroviral drug classes consist-
ing of two NRTIs and a third agent, either a protease in-
hibitor (PI) or a non-nucleoside reverse transcriptase
inhibitor (NNRTI) or an integrase inhibitor (INI), is rec-
ommended for first-line therapy [17,18]. During the last
decade, it has been recommended that all first-line NRTI
combinations contain an element of a thiacytidine medi-
cation (TCM), either lamivudine (3TC) or emtricitabine
(FTC) [17,19,20]. The two medications are interchange-
able, but because of their high antiretroviral similarity
with no additional effects, concomitant use should be
avoided [17]. NRTI-free regimen such as PI monother-
apy are not recommended because of inferior antiviral
potency [17,18,21-23]. Because standard ART consists of
a combination of at least three antiretroviral drugs given
in a multitude of combination regimens, it is impossible
to estimate the number of people receiving ART pre-
scriptions based on all single drugs [24]. However, virtu-
ally all ART regimens prescribed in different studies in a
setting of daily clinical practice contain exactly one
TCM [25-33]. Thus, each daily TCM documented in the
APD may be assumed to be representative of one person
per day treated with ART. It was hypothesised that the
ART regimens and treatment interruptions recorded in
the CSH were representative of people living with HIV
under antiretroviral treatment in Germany and that the
prescriptions covered by SHI were comparable with
those that were not.
This study used available prescription data sources
from both pharmacy billing centres and the CSH to de-
termine the number of people living with HIV currently
receiving ART, the number of HIV-infected people with
ART experience, and the differences in those numbers
over time between 2006 and 2013.
Methods
Data sources used for analysis
ART prescription data (APD)
ART prescription data were provided by Insight Health™
for the years 2006–2013. The data were collected on a
monthly basis from billing centres that processed all re-
imbursed prescriptions from pharmacies based on the
date of redemption at the counter. The provider claimed
a coverage of >99% within the SHI prescription market.
The recorded numbers of prescribed standard units (i.e.,
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for this study.
Defined daily doses (DDDs) were determined as rec-
ommended in the treatment guidelines [17]. The num-
ber of prescribed DDDs was calculated for TCMs
depending on the doses of standard units. According to
our approach, a DDD that included a TCM represented
one person-day, assuming that one person was treated
with TCM continuously every day for a quarter, as is rec-
ommended by treatment guidelines. In the case of the
prescription of a 150 mg dose of lamivudine, 2 tablets
were equivalent to one DDD.
The German ClinSurv HIV cohort (CSH)
The Clinical Surveillance of HIV Disease is a nationwide
multi-centre, open, long-term observational cohort study
for the clinical surveillance of HIV in Germany. The
CSH was initiated in 1999 as collaboration between
major HIV treatment centres and the Robert Koch Insti-
tute (RKI) which serves as the coordinating institution.
Anonymised data on patient demographics, detailed in-
formation on antiretroviral treatment, laboratory param-
eters and clinical events are collected biannually in a
standardised format. The study design is described in
detail elsewhere [14]. In the study period 2006–2013, an
average number of 10.400 patients were observed and
consecutively monitored at 15 clinical centres in various,
predominantly urban areas in Germany. Antiretroviral
treatment history, including any interruptions in treat-
ment, is documented in detail in the CSH [14,24]. Treat-
ment duration is calculated individually according to the
beginning and end dates of each antiretroviral drug
treatment. All ART documentation is assessed manually.
Quality control algorithms are applied, and in the case
of inconsistencies, the centres are requested to submit
the revised data to the RKI [14].
The Robert Koch Institute is the German national
public health institute, therefore the Federal Commis-
sioner for Data Protection is the responsible entity for
studies which are conducted by the Robert Koch Insti-
tute. Information on HIV infection collected in ClinSurv
corresponds to the data reported to the RKI according
to legal requirements implemented by the national Pro-
tection against Infection act (IfSG) of 2001. All patient
data collected in ClinSurv are generated during routine
care. The German Federal Commissioner for Data Pro-
tection therefore waived the need for ethical approval
for the ClinSurv study. No written informed consent is
required from patients.
The overall person-days observed from persons receiv-
ing any antiretroviral treatment between 2006 and 2013
in the CSH were analysed and categorised into three
groups: medications that contained approved drugs,
medications that contained at least one non-approveddrug, and interrupted therapy. In the first group, we distin-
guished between regimens that did include a TCM and
those without TCM. The numbers of all of these groups
were calculated quarterly. Treatment interruption was de-
fined as any observation time between therapy initiation
and latest observed event with documented treatment
discontinuation.
For the analysis of ART regimen in the CSH we sepa-
rated mainly used regimens and minor regimens. Mainly
used regimens were either defined as ART regimen con-
taining two or three NRTIs and another drug class
(NNRTIs, PIs, INIs) or two or three NRTIs exclusively.
Minor regimens were those including more than three
NRTIs and NRTI-free regimen.
Combination of data sources
Determining the number of people living with HIV receiving
ART
The number of prescribed DDDs of TCMs derived from
ART prescription data was used to determine the num-
ber of people living with HIV receiving quarterly SHI-
covered TCM containing ART in Germany. The propor-
tion of persons covered by SHI was calculated for each
federal state based on the number of persons with SHI
and the population number of the respective state. To
account for patients without SHI (including those pri-
vately insured, uninsured, or receiving free medical care)
whose prescriptions were not covered in the APD, the
number of patients was raised in average by a weighted
factor of 16.3% [34]. By adding the numbers of person-
days of non-TCM ART segments derived from the CSH,
we determined the total number of people living with
HIV receiving quarterly ART in Germany. In addition,
considering the proportion of person-days with treat-
ment interruption seen in the CSH yielded the number
of patients in Germany with ART experience. For an
overview of the investigated data sources, see Figures 1
and 2.
The estimated number of HIV-infected persons with
ART experience was smoothed using a negative bino-
mial regression with quadratic time trend in the period
of 2006 to 2013. The statistical errors of these numbers
were assumed to be independent. The independent vari-
ables considered in the negative binomial regression
were the time - measured in quarters since the first
quarter in year 2006 - and the square of this time. The
latter variable allowed us to adjust for a slowing down
of the exponentially increasing trend in the recent
years.
Results
ClinSurv HIV cohort (CSH)
The proportion of person-days with TCM-containing
regimens reported in the CSH increased continuously
SHI insured persons
~86% of the population
PHI & 
uninsured
PLWHA in Germany 
(number unknown, estimated ~ 78.000)
ART prescription data (APD)
ClinSurv cohort (20% of the population) 
detailed ART data (patients & regimens)
Figure 1 Schematic overview of subpopulations and available
data sources in Germany. Approximately 85% of the population in
Germany is covered by statutory health insurance (SHI), most of the
remainder are covered by private health insurance (PHI) and a small
proportion are uninsured (exact number unknown). For persons
covered by the SHI, antiretroviral prescriptions are recorded and
reported through antiretroviral prescription data (APD). The German
ClinSurv HIV cohort (CSH) contains detailed ART history data on
approximately 20% of people living with HIV in Germany receiving
ART, both those who are covered by SHI and those who are not.
This schematic is not to scale.
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Figure 2 Process diagram of used data sources and calculation steps
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2013/IV. In contrast, the proportion of person-days
with any observed treatment interruption declined from
11% in 2006/I to 2% in 2013/IV. The proportion of
person-days with an antiretroviral regimen that con-
tained non-approved drugs decreased from 6% in 2006/
I to 2% in 2013/IV (Table 1).
The exact composition of ART regimens of the CSH
is shown in Figure 3. The proportion of non-TCM regi-
men among NRTI/NNRTI and NRTI/PI dramatically
decreased over the study period. Non-TCM regimens
were most frequently observed among minor regimen
which was the only group with a slight increase of only
1% over the study period. The differentiated analyses of
the group minor regimens without TCM showed that
over the study period, the proportion of any non-
TCM-NRTI containing regimen (TCM-NRTI [+X]) as
well as the proportion of regimens consisting of two
PIs or PI monotherapy decreased, whereas the dual
combinations PI/AI, PI/II and other NRTI-free regi-
mens increased continuously from 2007 to 2013
(Figure 4).Antiretroviral prescription data (APD)
The number of TCM-containing prescriptions increased
from 1,778,070 prescribed DDDs in 2006/I to 3,838,620
prescribed DDDs in 2013/IV. of patients in  
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ithout TCM 
 of non- 
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2006/I 8717 6986 753553 613673 8211 131728 516827 29909 66937 81.4% 84.5% 10.9%
2006/II 8856 7104 773115 630625 7907 134629 533732 32431 64462 81.6% 85.3% 10.2%
2006/III 9002 7214 792169 646716 7742 137766 547485 36102 63129 81.6% 86.2% 9.8%
2006/IV 9075 7281 803312 655415 7530 140415 558719 36453 60243 81.6% 87.0% 9.2%
2007/I 9267 7434 798257 652832 7219 138281 560733 33462 58637 81.8% 87.7% 9.0%
2007/II 9407 7552 820040 671081 7345 141682 579930 33382 57769 81.8% 88.4% 8.6%
2007/III 9564 7689 844690 690514 7304 146945 595635 38313 56566 81.7% 89.1% 8.2%
2007/IV 9683 7828 855138 704369 6948 143877 609239 39403 55727 82.4% 89.5% 7.9%
2008/I 9758 7937 853480 705518 6344 141676 619880 31297 54341 82.7% 89.8% 7.7%
2008/II 9903 8069 863850 716324 5985 141595 632750 31325 52249 82.9% 90.4% 7.3%
2008/III 10031 8206 884551 737289 5895 141423 656479 28383 52427 83.4% 90.7% 7.1%
2008/IV 10124 8340 896771 752357 5982 138495 678973 22195 51189 83.9% 91.0% 6.8%
2009/I 10222 8484 886182 747140 5303 133792 677700 21820 47620 84.3% 91.3% 6.4%
2009/II 10384 8624 910943 769502 4859 136659 700526 21972 47004 84.5% 91.6% 6.1%
2009/III 10569 8814 934456 791390 4779 138362 722970 22322 46098 84.7% 91.8% 5.8%
2009/IV 10697 8989 946177 808947 4660 132635 742278 22853 43816 85.5% 92.0% 5.4%
2010/I 10799 9140 936276 805104 4473 126765 741693 22313 41098 86.0% 92.3% 5.1%
2010/II 10956 9290 958828 827947 4376 126573 768583 21791 37573 86.3% 92.4% 4.5%
2010/III 11123 9468 980925 849665 4289 127041 792663 21195 35807 86.6% 92.4% 4.2%
2010/IV 11171 9617 989771 865271 3898 120674 808229 22985 34057 87.4% 92.3% 3.9%
2011/I 11258 9761 974608 859468 3418 111790 803378 24123 31967 88.2% 92.3% 3.7%
2011/II 11333 9870 994656 880602 3347 110776 824465 25470 30667 88.5% 92.3% 3.5%
2011/III 11467 10030 1013429 901100 3305 109118 845603 26049 29448 88.9% 92.4% 3.3%
2011/IV 11480 10089 1021398 910156 3063 108245 857736 24301 28119 89.1% 92.5% 3.1%
2012/I 11588 10196 1014121 906295 3068 104831 858296 21730 26269 89.4% 92.6% 2.9%
2012/II 11612 10261 1019125 914177 2916 102114 867192 20862 26123 89.7% 92.6% 2.9%
2012/III 11651 10338 1032814 929619 2661 100626 883234 21460 24925 90.0% 92.4% 2.7%
2012/IV 11574 10334 1023954 925347 2423 96245 882817 20421 22109 90.4% 92.5% 2.4%
2013/I 11428 10229 980141 890397 2109 87707 852262 18571 19564 90.8% 92.7% 2.2%
2013/II 11092 9978 960764 876969 1508 82345 843148 16594 17227 91.3% 92.8% 2.0%
2103/III 10760 9725 879002 804520 1199 73313 775500 14296 14724 91.5% 92.7% 1.8%
2013/IV 8358 7610 363973 331301 621 31848 317585 7227 6489 91.0% 92.5% 2.0%
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Figure 3 Composition of ART regimens of patients in the ClinSurv HIV cohort.
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to the number of patients receiving SHI covered TCM con-
taining ART. We observed a systematic seasonal variation,
with a disproportionately high number of prescriptions in
the last quarter of each year. The number of patients re-











Figure 4 Composition of minor non-TCM containing ART regimens of19,756 persons in 2006/I to 41,724 persons in 2013/IV. The
proportion of persons covered by SHI was different in the
respective federal states and ranged from approximately
80% to 90%. The weighted proportion of persons covered
by SHI used for the calculation was on average 83.7% over






patients in the ClinSurv HIV cohort.
Table 2 German population, SHI coverage and calculated weighted SHI-coverage factor
Year/quarter German population Number of people in SHI SHI-coverage nationwide Weighted SHI-coverage factor
2006/I 82314906 70013157 85.1% 83.2%
2007/I 82217837 70022112 85.2% 83.5%
2008/I 82002356 69952132 85.3% 83.4%
2009/I 81802257 69719142 85.2% 84.1%
2010/I 81751602 69473638 85.0% 84.3%
2011/I 81843743 69311329 84.7% 83.3%
2012/I 81843743* 69398840 84.8% 83.9%
2013/I 81843743* 69521912 84.9% 84.0%
*updated data for 2012 and 2013 not available yet.
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receiving ART
After accounting for patients without SHI by adding
16.3% to the patient numbers derived from APD, the
numbers of people living with HIV receiving TCM-
containing ART in Germany were 23,751 in 2006/I and
increased to 49,719 in 2013/IV. By compensating for
regimens not containing TCMs, the number of all
people living with HIV receiving ART was estimated at
28,101 in 2006/I and increased continuously to 53,776 in
2013/V. Taking into account those who had interrupted
therapy led to the total number of HIV-infected people
with ART experience in Germany. Due to the observed
seasonal variation, we smoothed the trend by using a
negative binomial regression with quadratic time trend.
The total number of all HIV-infected people with ART
experience in Germany increased from 31,500 (95% CI
31,000-32,000) in the first quarter of 2006 to 54,000
(95% CI 53,000-55,500) individuals by the end of 2013
(Table 3 and Figure 5). The average difference between
the number of patients in Germany who had initiated
ART and those who had left observation because of emi-
gration or death was estimated to be an average of 2,900
persons per year.
Discussion
We estimated the number of people living with HIV
who received ART based on SHI prescription data and
on ART history data from the CSH. An underlying as-
sumption was that the ART regimens and treatment in-
terruptions recorded in the CSH would similarly apply
to HIV-infected people outside of the cohort and that
the prescription numbers in the APD would be compar-
able with all people living with HIV in Germany.
In the 2006–2013 observation period, substantial in-
creases were observed for the number of people living with
HIV receiving ART and for the number of HIV-infected
people with ART experience in Germany. Concomitantly,
the use of regimens that included TCMs increased con-
tinuously, whereas treatment interruptions in the CSH de-
creased remarkably.In an earlier estimation approach by Kollan et al., the
calculation was based on the daily drug dosages of all
substances. In our opinion, the new approach of calcu-
lating the number of individuals based mainly on unam-
biguous drugs (TCMs in this study) offers a simple and
appropriate method that could be further adapted for
other investigations.
At the beginning of the observation period, the per-
centage of CSH regimens that did not include TCMs
was 15%, and it decreased by half over time.
In Germany and other industrialised countries with a
large number of available antiretroviral drugs, the share
of TCMs would need to be taken into account when
using this approach to estimate the number of people
living with HIV under antiretroviral treatment. However,
in countries with fewer antiretroviral drug options, the
number of people living with HIV receiving ART could
potentially be calculated exclusively using the number of
delivered TCMs, which would be a reliable and simple
estimation method. Assuming that the proportion of
TCM use in Germany will continue to increase, this ap-
proach could become even more effective for calculating
German estimates.
The total number of all HIV-infected people with ART
experience in Germany was estimated to be 31,500 in the
first quarter of 2006 and increased continuously to 54,000
individuals by the end of 2013. According to our estima-
tion, the observed study population of the CSH represents
more than 20% of all treated patients in Germany. In the
CSH all patients who are seen in the centres are automatic-
ally included into the cohort without the need for written
informed consent. The CSH is therefore the least biased
source available and is the largest nationwide cohort of
HIV-positive patients. Nonetheless, the CSH in this study is
only used to determine the corresponding proportion of
non-TCM and treatment interruptions. In our opinion, the
demographics do not affect the TCM proportion of those
with access to ART. In order to verify this approach with
regard to more uncommon ART regimens and first-line
subsequent regimens we analysed the composition of regi-
mens of the CSH patients. As shown, the vast majority of

































95% CI 95% CI PT_E
smoothed and rounded
N (95% CI)
2006/I 90 1778070 19756 83.2% 23751 84.5% 28101 10.9% 31547 31505 30796 32229 31500 (31000-32000)
2006/II 91 1910070 20990 83.2% 25222 85.3% 29586 10.2% 32953 32198 31559 32848 32000 (31500-33000)
2006/III 92 1975770 21476 83.1% 25824 86.2% 29960 9.8% 33203 32896 32321 33480 33000 (32500-33500)
2006/IV 92 2114310 22982 83.1% 27641 87.0% 31757 9.2% 34971 33600 33082 34125 33500 (33000-34000)
2007/I 90 1982490 22028 83.5% 26385 87.7% 30092 9.0% 33064 34310 33838 34787 34500 (34000-35000)
2007/II 91 2106480 23148 83.3% 27776 88.4% 31434 8.6% 34396 35024 34588 35465 35000 (34500-35500)
2007/III 92 2174850 23640 83.3% 28383 89.1% 31844 8.2% 34687 35743 35330 36159 35500 (35500-36000)
2007/IV 92 2326950 25293 83.3% 30377 89.5% 33926 7.9% 36841 36467 36066 36872 36500 (36000-37000)
2008/I 91 2204460 24225 83.4% 29023 89.8% 32312 7.7% 35009 37195 36794 37600 37000 (37000-37500)
2008/II 91 2418270 26574 83.5% 31814 90.4% 35196 7.3% 37964 37926 37516 38339 38000 (37500-38500)
2008/III 92 2498580 27158 84.3% 32211 90.7% 35508 7.1% 38226 38661 38237 39089 38500 (38000-39000)
2008/IV 92 2680710 29138 84.2% 34578 91.0% 38009 6.8% 40781 39399 38957 39845 39500 (39000-40000)
2009/I 90 2562540 28473 84.1% 33844 91.3% 37072 6.4% 39595 40139 39678 40604 40000 (39500-40500)
2009/II 91 2719650 29886 84.1% 35529 91.6% 38809 6.1% 41336 40882 40403 41366 41000 (40500-41500)
2009/III 92 2792580 30354 84.3% 36015 91.8% 39239 5.8% 41667 41627 41132 42127 41500 (41000-42000)
2009/IV 92 2980560 32397 84.0% 38544 92.0% 41876 5.4% 44274 42374 41866 42887 42500 (42000-43000)
2010/I 90 2829630 31440 84.3% 37290 92.3% 40385 5.1% 42556 43121 42605 43643 43000 (42500-43500)
2010/II 91 2952420 32444 84.0% 38619 92.4% 41794 4.5% 43783 43869 43348 44396 44000 (43500-44500)
2010/III 92 3060450 33266 84.1% 39564 92.4% 42800 4.2% 44681 44618 44096 45146 44500 (44000-45000)
2010/IV 92 3208470 34875 84.0% 41494 92.3% 44947 3.9% 46790 45367 44847 45892 45500 (45000-46000)
2011/I 90 3021690 33574 83.3% 40316 92.3% 43696 3.7% 45388 46115 45599 46636 46000 (45500-46500)
2011/II 91 3162900 34757 83.2% 41771 92.3% 45256 3.5% 46888 46862 46349 47379 47000 (46500-47500)
2011/III 92 3301830 35889 83.2% 43160 92.4% 46721 3.3% 48301 47607 47095 48124 47500 (47000-48000)
2011/IV 92 3414960 37119 83.2% 44619 92.5% 48217 3.1% 49756 48351 47832 48874 48500 (48000-49000)
2012/I 91 3268320 35916 83.9% 42827 92.6% 46271 2.9% 47652 49092 48555 49634 49000 (48500-49500)
2012/II 91 3356700 36887 83.8% 44007 92.6% 47543 2.9% 48944 49831 49260 50407 50000 (49500-50500)
2012/III 92 3447960 37478 83.6% 44816 92.4% 48483 2.7% 49819 50566 49942 51197 50500 (50000-51000)
2012/IV 92 3632040 39479 83.6% 47240 92.5% 51089 2.4% 52344 51298 50599 52006 51500 (50500-52000)
2013/I 90 3467760 38531 84.0% 45861 92.7% 49478 2.2% 50591 52026 51230 52834 52000 (51000-53000)
2013/II 91 3657690 40194 84.0% 47861 92.8% 51555 2.0% 52585 52748 51834 53677 52500 (52000-53500)
2103/III 92 3768660 40964 84.0% 48791 92.7% 52657 1.8% 53639 53466 52413 54539 53500 (52500-54500)





























People living with HIV
receiving ART in Germany




Figure 5 SHI-covered TCM prescriptions and estimated numbers of HIV infected people with ART experience in Germany, 2006 to
2013. Step by step estimation of the number of HIV-infected people with ART experience shown as smoothed and rounded numbers, exact
numbers are shown in Table 3.
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clude two or three NRTIs and another drug class such as
NNRTIs, PIs, INIs (Figure 3). This applies for first-line
therapies as well as for following regimens considering we
pooled all data of CSH patients together for the analysis of
ART regimens, and therefore regimens after first-line ther-
apy naturally had a greater impact. Non-TCM regimens
were most frequently observed within the group minor
regimen which was also the only group with a slight in-
crease of only 1% over the study period. Until 2010, within
the minor regimen group double or mono PIs and non-
TCM-NRTI containing regimens were most frequently ob-
served, and from 2010 to the end of the observation period
NRTI-sparing regimens, e.g. PI/AI and PI/INI continuously
increased. If the prescribing patterns regarding regimens
without TCMs would change in the future then this would
have to be considered for our approach. However, this is
not the case for the described study period.
It is interesting to note the considerable decline in
CSH treatment interruptions. This reflects recent find-
ings showing that there are more risks than benefits
from so-called drug holidays [35-37]. In current HIV
treatment guidelines, structured treatment interruptions
are no longer recommended and are only considered in-
dividually under special circumstances [38]. However,
currently between 2% of interruption time is apparently
an inevitable fact.
In the APD data, we observed a systematic seasonal ef-
fect, with the fewest prescriptions at the beginning ofeach year and the most by the end of the year. We
speculate that this effect may be caused by differing pa-
tient demand driven by practical considerations with re-
gard to the beginning of the new year (i.e., Christmas
holidays, closing of medical offices) and/or prescription
co-payments whose reimbursements depend on the an-
nual amounts of all individual co-payments within a cal-
endar year.
Our approach may lead to an overestimation of the
number of people receiving continuous ART by patients
receiving only short-term ART. This might be relevant
in case of discontinuation of therapy early in a quarter
or when patients received a PEP.
When a person discontinued therapy before the medi-
cation was consumed, we counted that person as some-
one who was treated, but this person would not get
prescriptions in the next quarter, and the overestimation
would have been offset in the next billing period.
Representative data regarding the number of PEP pre-
scriptions are rare. Studies regarding PEP are often per-
formed in certain populations with limited significance
for the general public. To account for the overestimation
resulting from PEP prescriptions, we attempted to deter-
mine the number of PEP prescriptions using available
studies and sources. We assumed that most PEP pre-
scriptions would come from physicians who were
authorised for the special care of patients with HIV/
AIDS according to the HIV/AIDS Quality Assurance
Agreement (§ 135 para 2 SGB V). According to our
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to be approximately 2400–2800 per year in Germany
[39,40]. Considering that 12 PEP prescriptions are neces-
sary to result in one patient treated per year, an overesti-
mation of approximately 200 to 233 patients in total
could have occurred. In terms of the total number of ap-
proximately 54,000 people living with HIV receiving
ART in Germany, the resulting overestimation would be
comparatively small.
On average, the increase in the number of people liv-
ing with HIV receiving ART was approximately 2,900
persons per year in Germany. This increase should not
be confused with the number of persons who initiated
therapy, but rather represents the difference between
people who initiated ART and those who discontinued
treatment because of emigration or death. Thus, the true
number of persons who began treatment is probably
higher than the observed difference.
The proportion of people covered by PHI differed
among the federal states. Those federal states with
higher PHI coverage, e.g. City-States, tend to be those
with a higher number of prescriptions. We therefore
used a weighted SHI-coverage factor based on the data
for each federal state and applied it to the antiretroviral
prescription data in order to improve the estimates.
Using the nationwide SHI-coverage factor would under-
estimate the total number by 1.6% (N = 650 persons).
With this study, we provide a nationwide estimate and
a useful tool for calculating the number of people living
with HIV who received ART, those with ART experience
and the increase in ART usage between 2006 and 2013
in Germany using the available number of prescriptions
and surveillance data from the CSH.
This approach can be useful to estimate the number of
people living with HIV and those receiving ART in other
countries. Additionally, the described methodology could
potentially be used and adapted for other investigations or
medications in the future.
Limitations
The described approach has some limitations. One limi-
tation is an overestimation resulting from the cases that
were discussed above. Of those cases, the number of
PEP prescriptions is the most uncertain, which could be
the main limitation.
Overall, our aim was to estimate the number of treated
patients among all persons with access to ART. We do
not aim to, and therefore do not, estimate the number
of non-treated patients among all people infected with
HIV in Germany.
Lamivudine is approved for the treatment of hepatitis
B with a dose of 100 mg once daily for persons not in-
fected with HIV. The use of lamivudine with approval
for HIV therapy (150 mg and 300 mg) in the treatmentof hepatitis B of HIV-negative individuals attributable to
economic considerations cannot be excluded. However,
the off-label use of HIV-labelled lamivudine would re-
quire an alternative dosing regimen by administration
on alternating days and/or by dividing the pills, which
we consider impractical in reality.
A limitation with regard to applying this approach in
the future is that if TCM prescribing patterns, such as
the currently discussed dual NRTI-sparing therapies, or
other treatment practices significantly change, the im-
pact of a second source (in our case, the CSH) on the
estimate would be greater.
Conclusions
This report describes the first comprehensive approach to
estimating the number of people living with HIV who re-
ceive ART. The study provides a possible approach for de-
termining the number of people receiving specialised HIV
medical care in Germany. This method allows for contrast-
ing the numbers of people living with HIV receiving ART
derived from different sources or estimation approaches.
This approach can be useful to estimate the number of
people living with HIV and those receiving ART in other
countries. The described methodology could be used and
adapted for different investigations or medications in the
future. Non-TCM regimens and CSH treatment interrup-
tions declined notably. Assuming that this trend will con-
tinue in the future, the number of people living with HIV
receiving ART could be estimated exclusively using TCM-
containing prescriptions. In other settings with fewer avail-
able antiretroviral drugs, the estimation would be even
more robust.
It is also of interest to note trends in antiretroviral ther-
apy with regard to NRTI-free regimens. In this context, the
relevance of data from cohort studies remains very high for
observing and assessing such developments.
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